GENOME EDITING and the CRISPR CRAZE



Author, Editing Humanity

Lexington KY | 02.25.2022

Conflicts of Interest


Nothing to declare.

Kevin Davies

Executive Editor, *The CRISPR Journal* Author, *Editing Humanity*

CRISPR














JENNIFER DOUDNA & EMMANUELLE CHARPENTIER ARE CO-INVENTORS OF THE REVOLUTIONARY TOOL CRISPR TO EDIT THESE IN THE BODY



The Nobel Prize in Chemistry 2020 awarded jointly to

Emmanuelle
Charpentier
and
Jennifer A.
Doudna

"for the development of a method for genome editing."

October 7, 2020





ARTICLES

Highly efficient endogenous human gene correction using designed zinc-finger nucleases

Fyodor D. Urnov¹, Jeffrey C. Miller¹, Ya-Li Lee¹, Christian M. Beausejour¹, Jeremy M. Rock¹, Sheldon Augustus¹, Andrew C. Jamieson¹, Matthew H. Porteus², Philip D. Gregory¹ & Michael C. Holmes¹


Permanent modification of the human genome in vivo is impractical owing to the low frequency of homologous recombination in human cells, a fact that hampers biomedical research and progress towards safe and effective gene therapy. Here we report a general solution using two fundamental biological processes: DNA recognition by C_2H_2 zinc-finger proteins and homology-directed repair of DNA double-strand breaks. Zinc-finger proteins engineered to recognize a unique chromosomal site can be fused to a nuclease domain, and a double-strand break induced by the resulting zinc-finger nuclease can create specific sequence alterations by stimulating homologous recombination between the chromosome and an extrachromosomal DNA donor. We show that zinc-finger nucleases designed against an X-linked severe combined immune deficiency (SCID) mutation in the $IL2R\gamma$ gene yielded more than 18% gene-modified human cells without selection. Remarkably, about 7% of the cells acquired the desired genetic modification on both X chromosomes, with cell genotype accurately reflected at the messenger RNA and protein levels. We observe comparably high frequencies in human T cells, raising the possibility of strategies based on zinc-finger nucleases for the treatment of disease.

Courtesy: HUMAN NATURE





An "unusual arrangement": CRISPR in *E. coli* (1987)







Fecha: Wed, 21 Nov 2001 16:39:06 +0100

De: "Ruud Jansen" < R.Jansen@vet.uu.nl>

Empresa: Diergeneeskunde

A: "Francisco J. Martínez Mojica" <fmojica@ua.es>

JOURNAL OF MULELULAR EVOLUTION

© Springer Science+Business Media, Inc. 2005

Dear Francis

What a great acronym is CRISPR.

I feel that every letter that was removed in the alternatives made it less crispy so I prefer the snappy CRISPR over SRSR and SPIDR. Also not unimportant is the fact that in MedLine CRISPR is a unique entry, which is not true for some of the other shorter acronyms.

Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic Elements

Francisco J.M. Mojica, César Díez-Villaseñor, Jesús García-Martínez, Elena Soria

División de Microbiología, Departamento de Fisiología, Genética y Microbiología, Universidad de Alicante, Campus de San Vicente, E-03080, Spain

Received: 6 February 2004 / Accepted: 1 October 2004 [Reviewing Editor: Dr. John Huelsenbeck]

CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes

Rodolphe Barrangou, ¹ Christophe Fremaux, ² Hélène Deveau, ³ Melissa Richards, ¹ Patrick Boyaval, ² Sylvain Moineau, ³ Dennis A. Romero, ¹ Philippe Horvath ²*

Science 2007








CRISPR

... is a natural bacterial immune defense system that provides a means to recognize, remember and destroy viral invaders.











Prashant Mali, 1* Luhan Yang, 1,3* Kevin M. Esvelt, 2 John Aach, 1 Marc Guell, 1 James E. DiCarlo, 4 Julie E. Norville, 1 George M. Church 1,2 †

Bacteria and archaea have evolved adaptive immune defenses, termed clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems, that use short RNA to direct degradation of foreign nucleic acids. Here, we engineer the type II bacterial CRISPR system to function with custom guide RNA (gRNA) in human cells. For the endogenous AAVS1 locus, we obtained targeting rates of 10 to 25% in 293T cells, 13 to 8% in K562 cells, and 2 to 4% in induced pluripotent stem cells. We show that this process relies on CRISPR components; is sequence-specific; and, upon simultaneous introduction of multiple gRNAs, can effect multiplex editing of target loci. We also compute a genome-wide resource of ~190 K unique gRNAs targeting ~40.5% of human exons. Our results establish an RNA-guided editing tool for facile, robust, and multiplexable human genome engineering.



Lights. Camera. Action... CUT!

CRISPR-Cas9
visualized by highspeed atomic force
microscopy



M. Shibata, H. Nishmasu et al.

Nature Communications 8, 1430 (2017)































Victoria Gray

Forest, Mississippi

First patient to receive CRISPR gene therapy for sickle-cell disease in the USA

- 46% total HbF
- 99.7% red blood cells contain some of it.

ORIGINAL ARTICLE BRIEF REPORT

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

Haydar Frangoul, M.D., David Altshuler, M.D., Ph.D., M. Domenica Cappellini, M.D., Yi-Shan Chen, Ph.D., Jennifer Domm, M.D., Brenda K. Eustace, Ph.D., Juergen Foell, M.D., Josu de la Fuente, M.D., Ph.D., Stephan Grupp, M.D., Ph.D., Rupert Handgretinger, M.D., Tony W. Ho, M.D., Antonis Kattamis, M.D., Andrew Kernytsky, Ph.D., Julie Lekstrom-Himes, M.D., Amanda M. Li, M.D., Franco Locatelli, M.D., Markus Y. Mapara, M.D., Ph.D., Mariane de Montalembert, M.D., Damiano Rondelli, M.D., Akshay Sharma, M.B., B.S., Sujit Sheth, M.D., Sandeep Soni, M.D., Martin H. Steinberg, M.D., Donna Wall, M.D., Angela Yen, Ph.D., and Selim Corbacioglu, M.D.

CRISPR Therapeutics | June 2020

In vivo Genome Editing

ORIGINAL ARTICLE

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

Julian D. Gillmore, M.D., Ph.D., Ed Gane, M.B., Ch.B., Jorg Taubel, M.D., Justin Kao, M.B., Ch.B., Marianna Fontana, M.D., Ph.D., Michael L. Maitland, M.D., Ph.D., Jessica Seitzer, B.S., Daniel O'Connell, Ph.D., Kathryn R. Walsh, Ph.D., Kristy Wood, Ph.D., Jonathan Phillips, Ph.D., Yuanxin Xu, M.D., Ph.D., Adam Amaral, B.A., Adam P. Boyd, Ph.D., Jeffrey E. Cehelsky, M.B.A., Mark D. McKee, M.D., Andrew Schiermeier, Ph.D., Olivier Harari, M.B., B.Chir., Ph.D., Andrew Murphy, Ph.D., Christos A. Kyratsous, Ph.D., Brian Zambrowicz, Ph.D., Randy Soltys, Ph.D., David E. Gutstein, M.D., John Leonard, M.D., Laura Sepp-Lorenzino, Ph.D., and David Lebwohl, M.D.

Genome Editing News Rare and Neglected Diseases "New Era of Medicine": Researchers Publish First Positive Clinical Data for In Vivo Genome Editing in Humans Intellia, Regeneron candidate NTLA-2001 shows sustained reduction in protein-

causing transthyretin (ATTR) amyloidosis after a single dose in six patients

TTR exon

Leu Leu Cys Leu Ala Gly Leu Val Phe Val Ser Glu Ala Gly ... |C T C|C T C|C T C|T |G C T|G C T|G G A|C T G|G T A|T T T|G T G|T |C T|G A G|G C T|G G C|...

CRISPR-Cas9 editing

Leu Leu Cys Leu Ala Trp Thr Gly Ile Cys Val STOP ... |C T C|C T C|C T C|T G C|C T T|G C T|T G G|A C T|G G T|A T T|T G T|G T C|T G A|G G C|T G G|C ...

frequent 1-bp insertion




An epic clash of cultures in ancient Mesoamerica p. 968


Music is another language pp. 974 & 1043 A primordial body in the Kuiper Belt pp. 980 & 998-1000

Sciencemag.org \$15 28 FEBRUARY 2020 sciencemag.org MAAAS

HUMAN

Gene editing meets





Editas CRISPR treatment improved vision for one patient, but not others, early data show

By Adam Feuerstein ♥ Sept. 29, 2021

Reprints









The world's most expensive medicine could save toddlers' lives. But getting it is complicated

By Jonathan Saltzman -- Boston Globe 8.8.19










Heterogeneous Diversity of Spacers within CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)

Jiankui He & Michael W. Deem

Phys. Rev. Lett. 105, 128102 – Published 14 September 2010

Chinese Scientists Edit Genes of Human Embryos, Raising Concerns



Huang Junjiu (Sun Yat-sen University) -- *New York Times* (2015)

Protein Cell 2015, 6(5):363–372 DOI 10.1007/s13238-015-0153-5



Protein & Cell

RESEARCH ARTICLE

CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes

Puping Liang, Yanwen Xu, Xiya Zhang, Chenhui Ding, Rui Huang, Zhen Zhang, Jie Lv, Xiaowei Xie, Yuxi Chen, Yujing Li, Ying Sun, Yaofu Bai, Zhou Songyang, Wenbin Ma, Canquan Zhou[⊠], Junjiu Huang[™]

Guangdong Province Key Laboratory of Reproductive Medicine, the First Affiliated Hospital, and Key Laboratory of Gene Engineering of the Ministry of Education, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China Correspondence: hjunjiu@mail.sysu.edu.cn (J. Huang), zhoucanquan@hotmail.com (C. Zhou)

Received March 30, 2015 Accepted April 1, 2015



ARTICLE

doi:10.1038/nature23305

Correction of a pathogenic gene mutation in human embryos

Hong Ma^{1*}, Nuria Marti-Gutierrez^{1*}, Sang-Wook Park^{2*}, Jun Wu^{3*}, Yeonmi Lee¹, Keiichiro Suzuki³, Amy Koski¹, Dongmei Ji¹, Tomonari Hayama¹, Riffat Ahmed¹, Hayley Darby¹, Crystal Van Dyken¹, Ying Li¹, Eunju Kang¹, A.-Reum Park², Daesik Kim⁴, Sang-Tae Kim², Jianhui Gong^{5,6,7,8}, Ying Gu^{5,6,7}, Xun Xu^{5,6,7}, David Battaglia^{1,9}, Sacha A. Krieg⁹, David M. Lee⁹, Diana H. Wu⁹, Don P. Wolf¹, Stephen B. Heitner¹⁰, Juan Carlos Izpisua Belmonte³§, Paula Amato^{1,9}§, Jin-Soo Kim^{2,4}§, Sanjiv Kaul¹⁰§ & Shoukhrat Mitalipov^{1,10}§

Genome edit the heterozy accuracy and response. Inc homologous the DSB was embryos carr safety of the a embryos by c applications,





The essential daily briefing

THURSDAY 27JULY 2017

Newscouk

Twin Peaty

Swimming hero wins second gold





Germanul Shenaur THE 📕 PAPER - BRITAIN'S FIRST AND ONLY CONCISE QUALITY TITLE

i world exclusive

One giant step for designer

» Revealed Era of genetically modified babies moves closer, as scientists prove they can safely alter human embryos

»Inherited diseases caused by defective genes can be corrected in the earliest stage of life, revolutionary technique shows

» Same technology could be used to select stronger muscles or better eyesight, prompting fierce ethical debate

"They've done it. The quality of the work is high," top scientist tells!

» Religious organisations likely to oppose groundbreaking research

SPECIAL REPORT BYSTEVE CONNOR, PAGES 6-7

INSIDE CAR BAN BACKLASH 200 I SCIENCE 200 I TV @ RADIO 200 I GAMES 200



Robert Edwards / Louise Brown









And here she is...

THE LOVELY LOUISE



LOUISE BROWN, bright-eyed at 18 hours old: The test tube baby in hospital yesterday



The "AIDS Village"

Wenlou Village Henan Province, China







"The Baby is Born"

Hi Stephen,

Great news! the baby is born (please keep it in confidential). I am coming to San Francisco this week, will you be available for a meeting? I can come to Stanford in Wednesday, Thursday or Friday. I want get help from you on how to announce the result, PR and ethics.

Regards, JK

Jiankui He
Associate Professor
Southern University of Science and Technology (SUSTech)
Lab website: www.sustc-genome.org.cn


贺建奎

南方科技大学生物系副教授




New York Times April 14, 2019









15 Reasons Why

SCIENCE

The CRISPR Baby Scandal Gets Worse by the Day

The alleged creation of the world's first gene-edited infants was full of technical errors and ethical blunders. Here are the 15 most damning details.

ED YONG DEC 3, 2018

- 7. A rew people knew about He's intentions but failed to stop him.
- 8. He acted in contravention of global consensus.
- 9. He acted in contravention of his own stated ethical views.
- 10. He sought ethical advice and ignored it.
- 11. There is no way to tell whether He's work did any good.
- 12. He has doubled down.
- 13. Scientific academies have prevaricated.
- 14. A leading geneticist came to He's defense.
- 15. This could easily happen again.



Birth Announcement

Birth of Twins After Genome Editing for HIV Resistance

Jinzhou Qin^{1,2,#}, Yangran Chen^{1,#}, Xiaoqing Zhou^{1,#}, Shuo Song^{1,#}, Kaijing Chen¹, Rui Chen¹, Yuanlin Chen¹, Hua Bai³, Michael W. Deem⁴, Jiankui He^{1,4}

A. Regalado Tech Review Dec 3, 2019

Abstract

Millions of children are born annually with inherited genetic diseases or infectious diseases acquired from parents. The recently developed CRISPR-Cas9 genome editing technique may provide an efficient and cost-effective therapeutic strategy to cure diseases with a genetic component. Genome editing at the embryonic stage has potential to permanently cure disease and confer resistance to pathogenic infections. Here, we report the first birth from human gene editing: twin girls who had undergone CCR5 gene editing as embryos were born normal and healthy in November 2018. Their father was an HIV carrier. We used CRISPR-Cas9 to reproduce a prevalent genetic variant of the CCR5 gene in fertilized oocytes during in vitro fertilization procedure, with the aim of helping the twins to be born with their own natural protection against HIV infection. Genome sequencing during pre-implantation genetic testing and after birth confirmed that the twins' CCR5 genes were edited successfully and are thus expected to confer either complete or partial HIV resistance. No off-targets, large deletions or pathogenic cancer gene mutations was observed. We here bring a novel therapy to enable acquired immunity to HIV and to control the HIV epidemic. We anticipate that human embryo genome editing will bring new hope to millions of families seeking healthy babies free from inherited or acquired life-threatening diseases.

المراط والماست المعالية والماستان والماسية

Department of Biology, Southern University of Science and Technology, Shenzhen, 518055, China.

² Department of Human Reproductive Medicine Center, Third Affiliated Hospital of Shenzhen University, Shenzhen 518001, China.

³ BaiHuaLin China People Living With HIV/AIDS Alliance, Cuipingli 10-132, Tongzhou, Beijing, China

Departments of Bioengineering and Physics & Astronomy, Center for Theoretical Biological Physics, and Graduate Program in Systems, Synthetic, and Physical Biology, Rice University, Houston, TX 77005, USA.

^{*}Corresponding Author. Email: hejk@sustc.edu.cn

[#]Equal contribution





HE JIANKUI


By Jennifer Doudna



Anthony Kwan-Bloomberg/Getty Images

"Going against the consensus... that CRISPR-Cas9 technology is still too experimental and dangerous to use in human embryos, he applied it to forever change the genomes of twin girls.... His reckless experimentation on the girls in China not only shattered scientific, medical and ethical norms, it was also medically unnecessary...

He's fateful decision to ignore the basic medical mantra of "do no harm" and risk the unintended consequences will likely be remembered as one of the most shocking misapplications of any scientific tool in our history."



HHGE Criteria

... should a country decide to permit them, are:

- 1. Limited to serious monogenic diseases (severe morbidity or premature death)
- 2. Limited to changing a pathogenic gene variant to a sequence common in the population and non-disease-causing
- 3. No healthy embryos to be subjected to HHGE
- 4. Limited to cases where prospective parents have no (or very poor) options for having a genetically related child.

 NAS/Royal Society

Sept 2020



Pirogov Medical University

Moscow



"Yesterday was early, tomorrow will be late.

Power must be taken today."

-- LENIN

Andrey Rudakov / Bloomberg

Who Wants a CRISPR Clinic?

From: "xxxxxxxxx"<xxxxxxxx;

Date: Wed, Dec 5, 2018 01:18 PM

Subject: CRISPR Gene Editing Embryology Lab Application Course

Dear He Jiankui,

Congratulations on your recent achievement of the first gene editing baby delivered by your application! My name is XXXXXXX, and I am the Business Director's Assistant at XXXXXXXX Fertility & Gynaecology Center, in Dubai.

Our Embryologist is interested in partaking in a course regarding CRISPR gene editing for Embryology Lab Application.

Does your facility offer this type of course?

Kind regards, XXXXXXXXXXX Business Director's Assistant XXXXXX





REPORT

Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9

Dong Niu^{1,2,*}, Hong-Jiang Wei^{3,4,*}, Lin Lin^{5,*}, Haydy George^{1,*}, Tao Wang^{1,*}, I-Hsiu Lee^{1,*}, Hong-Ye Zhao³, Yong Wang⁶, Yinan Kan¹, Ellen Shrock⁷, Emal Lesha¹, Gang Wang¹, Yonglun Luo⁵, Yubo Qing^{3,4}, Deling Jiao^{3,4}, Heng Zhao^{3,4}, Xiaoyang Zhou⁶, Shougi Wang⁸, Hong Wei⁶, Marc Güell^{1,†}, George M. Church^{1,7,9,†}, Luhan Yang^{1,†,‡}

¹eGenesis, Inc., Cambridge, MA 02139, USA.

The UCSD Insectary **GENE DRIVES** Cas9 Cargo Cas9 Cargo Repair **Cut site** Cas9 Cargo Allele 2 Gene drive inheritance Normal inheritance Altered gene does not spread Altered gene is always inherited Omar Akbari



Genome Edited Plants



Caixia Gao (Chinese Academy Sciences)

Zach Lippman (CSHL/HHMI)

Tomato is first CRISPR-edited food to go on sale in the world













ENVIRONMENT 24 September 2021

By Michael Le Page



Tomatoes with genes edited by CRISPR technology are now on sale in Japan

For the first time ever, you can now buy a food altered by CRISPR gene editing – at least, if you live in Japan, where the Sicilian Rouge High GABA tomato has just gone on sale.

"We started shipping the tomatoes on September 17," says Minako Sumiyoshi at Japanese start-up Sanatech Seed, which is selling the tomatoes directly to consumers. She says demand for the tomatoes is "not too bad".

"It is a very significant milestone for CRISPR foods," says ...

The first CRISPR geneedited food has gone on sale in Japan recently, in the form of a tomato packed with an <u>alleged increase in</u> nutritional content.

The Sicilian Rouge High GABA tomato, created by startupSanatech Seed, sold geneedited seedlings to any farmers that wanted them earlier in the year, and 4,200 farmers took up the offer. Now, the tomatoes are ripe for sale.
















ANIMAL AND PLANT SPECIES ARE THREATENED WITH EXTINCTION.

According to Leading Scientists;

◎ (*) ●



30,000

species per year on average are being driven to extinction.

Per hour

150

Per day

Up To

55,000

Per year



50%

The World Animal Foundation predicts that up to

ONE-HALF OF ALL SPECIES

could become extinct by 2050.





















Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage

Alexis C. Komor^{1,2}, Yongjoo B. Kim^{1,2}, Michael S. Packer^{1,2}, John A. Zuris^{1,2} & David R. Liu^{1,2}




Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage

Nicole M. Gaudelli^{1,2,3}, Alexis C. Komor^{1,2,3}†, Ho‼y A. Rees^{1,2,3}. Michael S. Packer^{1,2,3}†, Ahmed H. Badran^{1,2,3}, David I. Bryson^{1,2,3}† & David R. Liu^{1,2,3}


A New Crispr Technique Could Fix Almost All Genetic Diseases

A less error-prone DNA editing method could correct many more harmful mutations than was previously possible.









GENE THERAPY

One-time CRISPR hit lowers cholesterol in monkeys

Verve Therapeutics demonstrates long-term LDL reduction for base editor therapy

by Alla Katsnelson, special to C&EN

May 19, 2021 | A version of this story appeared in Volume 99, Issue 19










HUMAN NATURE












THE AUTHOR OF CRACKING THE GENOME UNRAVELS
ONE OF THE MOST IMPORTANT BREAKTHROUGHS
IN MODERN SCIENCE AND MEDICINE.



"With great reporting and deep knowledge, science journalist Kevin Davies takes us to all the frontlines of CRISPR research, from gene editing to improved agriculture. It's the scientific revolution of our era, and Davies gives us a close-up view of all the important players and exciting discoveries."

— WALTER ISAACSON, author of Steve Jobs and The Innovators

Davies dissects the implications CRISPR will have on our everyday lives and the lives of generations to come.



E: davieskev@gmail.com

T: @KevinADavies



